Detailed Study Notes for Unit V

Unit-V: Patent Law — The Patents Act, 1970

1. Concept of Patent & Historical Overview in India

A. Conceptualizing a Patent

Definition: A patent is a statutory monopoly right granted by the sovereign government to an inventor, giving them the exclusive right to exclude others from making, using, offering for sale, selling, or importing the patented invention for a limited period of time (typically 20 years from the date of filing).
The Quid Pro Quo Principle: A patent is granted on the principle of a bargain between the inventor and society: the inventor receives a time-bound commercial monopoly, and in exchange, they must provide a complete, enabling disclosure of the invention to the public so that knowledge enters the public domain upon patent expiry.

B. Historical Evolution of Patent Law in India

Colonial Roots: The first Indian patent legislation was enacted by the British in 1856 (Act VI of 1856) based on British patent statutes.
The Patents Act, 1970: Following independence, the Ayyangar Committee Report revealed that foreign multinational corporations held over 90% of Indian patents, blocking domestic industrial growth, charging exorbitant prices for medicines, and stifling local manufacturing. This led to the enactment of The Patents Act, 1970, which revolutionized Indian patent law by abolishing product patents for pharmaceuticals and chemicals, allowing only process patents, and reducing patent terms to encourage generic drug manufacturing and domestic industrial self-reliance.
The 2005 Amendment (TRIPS Compliance): To comply with WTO-TRIPS obligations, India amended the Patents Act in 2005, re-introducing product patents for pharmaceuticals, food, and chemicals, while incorporating strong public health safeguards.

2. Patentable Inventions & Statutory Exceptions (Sections 2(1)(j) and Section 3)

A. Core Criteria of Patentability (Section 2(1)(j))

For an invention to be patentable under Indian law, it must satisfy three mandatory statutory tests:

Novelty (New Invention): The invention must not form part of any existing prior art (publicly known or published anywhere in the world prior to the date of filing).
Inventive Step (Non-obviousness): The invention must involve a technical advancement compared to existing knowledge or have economic significance that would not be obvious to a person skilled in the art.
Industrial Applicability: The invention must be capable of being made or used in any kind of industry.

B. Statutory Non-Patentable Inventions (Section 3)

Section 3 expressly excludes certain innovations from patent protection:

Frivolous inventions or inventions contrary to public order or morality.
The mere discovery of a scientific principle, abstract theory, or living microorganism occurring in nature.
Section 3(d): The mere discovery of a new form of a known substance which does not result in the enhancement of the known efficacy of that substance (barring pharmaceutical “evergreening”).
Methods of agriculture or horticulture.
Any process for the medicinal, surgical, curative, or prophylactic treatment of human beings or animals.

3. Procedure for Obtaining a Patent in India

Filing an Application (Section 6 & 13): Filed by the true and first inventor (or assignee) before the Indian Patent Office (Mumbai, Delhi, Kolkata, or Chennai) as either a Provisional Specification (securing priority date with initial description) or a Complete Specification (with full claims).
Publication (Section 11A): Published in the Official Patent Journal usually 18 months from the date of filing.
Request for Examination (Section 11B): The applicant must file a formal request for examination within 48 months, following which a patent examiner scrutinizes the application for novelty and compliance.
Pre-Grant Opposition (Section 25(1)): Any person can file a representation opposing the patent before the patent is granted.
Grant and Seal (Section 43): Upon successful clearance, the patent is granted, entered in the Register of Patents, and published. (Post-grant opposition under Section 25(2) is available within 1 year of grant).

4. Rights and Obligations of a Patentee & Limitations

A. Rights of a Patentee (Section 48)

Exclusive right to prevent third parties from making, using, offering for sale, selling, or importing the patented product or process without consent.

B. Obligations and Statutory Limitations on Patent Rights

Compulsory Licensing (Sections 84 to 92): To prevent abuse of patent monopoly (such as failure to meet public demand, unreasonably high pricing, or failure to work the patent in India), any interested person can apply to the Controller for a Compulsory License after 3 years from patent grant, allowing them to manufacture the patented product without the patentee’s consent.
Government Use (Section 100 & 102): The Central Government can use patented inventions for governmental purposes or acquire patents outright in national emergencies.
Secrecy Directions (Section 35): The government can withhold patent grants for inventions relevant to national defense.

5. Infringement of Patent Rights and Remedies

What Constitutes Infringement: Unauthorized manufacture, use, sale, or importation of a patented invention during the subsistence of the patent.
Civil Remedies (Section 108):
- Interim and permanent injunctions restraining infringement.
- Award of damages or an account of profits.
- Order for seizure, forfeiture, or destruction of infringing goods.
Note on Courts: Patent infringement suits must be instituted before a District Court or specialized High Court Commercial Division.

6. In-Depth Landmark Case Studies

Case Study 1: Patentability Threshold and Anti-Evergreening (Section 3(d))

Case Title: Novartis AG v. Union of India
Citation & Court: (2013) 6 SCC 1 (Supreme Court of India)
Related Statutory Sections: Section 3(d) and Section 2(1)(j) of the Patents Act, 1970.
The Story & Real-Life Background: Swiss pharmaceutical multinational Novartis sought a patent for the beta-crystalline form of imatinib mesylate (marketed as Glivec), an anti-cancer drug. The Indian Patent Office rejected the application under Section 3(d) because it was merely a new crystal form of a known substance without proven enhanced therapeutic efficacy. Novartis challenged the rejection, arguing that enhanced bioavailability constitutes inventive efficacy.
Legal Issues Involved: The exact legal interpretation of “enhanced efficacy” under Section 3(d) and whether incremental modifications of known drugs qualify for patent protection in India.
Final Judgement & Ratio Decidendi:
- Ruling: The Supreme Court ruled against Novartis, holding that the beta-crystalline form did not show any therapeutic efficacy enhancement over the known substance. The court affirmed that Section 3(d) was enacted by Parliament specifically to prevent the “evergreening” of patents on pharmaceutical drugs, balancing corporate innovation with affordable public access to life-saving medicines.
- Ratio: Incremental pharmaceutical modifications that lack demonstrable therapeutic efficacy enhancement are unpatentable under Indian law.

Case Study 2: First Compulsory Licensing Order in India

Case Title: Bayer Corporation v. Cipla Ltd. (Natco Pharma v. Bayer Corporation)
Citation & Court: Compulsory License Application No. 1 of 2011 (Controller General of Patents, Mumbai)
Related Statutory Sections: Section 84 of the Patents Act, 1970.
The Story & Real-Life Background: Bayer patented Nexavar (sorafenib tosylate), a life-saving kidney and liver cancer drug, and sold it at an exorbitant price (approx. Rs. 2.8 Lakhs per month). Bayer imported small quantities and failed to manufacture the drug locally in India. Natco Pharma filed for India’s first Compulsory License, offering to sell the generic version at a fraction of the cost (approx. Rs. 8,800 per month).
Legal Issues Involved: The statutory grounds for granting a compulsory license when a patented drug is priced unaffordably and not locally manufactured.
Final Judgement & Ratio Decidendi:
- Ruling: The Controller of Patents granted India’s first compulsory license to Natco Pharma, holding that Bayer failed to make the drug available to the public at a reasonably affordable price and failed to manufacture it locally within India.
- Ratio: Patent monopolies carry social obligations; if a patentee fails to make life-saving drugs reasonably accessible and affordable, statutory compulsory licensing mechanisms will be invoked to protect public health.

Quick Reference Guide: Unit-V Patent Act

Unit Number	Act / Statute Name	Relevant Sections Range	Core Description / Subject Matter
Unit-V	The Patents Act, 1970	Sections 1 to 162	Patentable criteria (Novelty, Inventive Step), Section 3(d) exceptions, procedure, compulsory licensing, and infringement remedies.